Lisinopril & Irbesartan Interaction

Lisinopril (an ACE inhibitor) and irbesartan (an angiotensin II receptor blocker) are both RAAS inhibitors. Combining two RAAS-blocking agents — often called dual RAAS blockade or dual blockade therapy — significantly increases risks of hyperkalemia, acute kidney injury, and hypotension without meaningful additional cardiovascular or renal benefit in most patients. Major guidelines and the FDA label for both drugs recommend against this combination in most settings.

Lisinopril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, thereby reducing aldosterone secretion and causing vasodilation and potassium retention. Irbesartan blocks AT1 angiotensin II receptors, also reducing aldosterone and causing vasodilation. Combining both drugs completely blocks angiotensin II signaling at two sequential points in the RAAS cascade, producing additive potassium retention (hyperkalemia risk) and more profound reduction in angiotensin II-mediated renal afferent glomerular regulation, increasing acute kidney injury risk.

The ONTARGET trial (N=25,000) demonstrated that telmisartan plus ramipril (dual RAAS blockade) provided no additional cardiovascular benefit versus monotherapy, but significantly increased adverse events: more hypotension, syncope, renal impairment, and hyperkalemia. Based on this evidence, the FDA updated prescribing information for both ACE inhibitors and ARBs to warn against combined use. The VA NEPHRON-D trial also confirmed increased risk of AKI and hyperkalemia with dual blockade in diabetic nephropathy.

Avoid concurrent use of lisinopril and irbesartan in most clinical scenarios. If both were prescribed for different indications, reassess whether one can be discontinued. If dual RAAS blockade was used for diabetic nephropathy (a historical practice), transition to single-agent RAAS blockade per current guidelines. If both are needed for a specific indication (rare), monitor kidney function and potassium very closely.

Serum potassium (weekly initially, then monthly). Serum creatinine and eGFR (weekly initially, then monthly). Blood pressure including orthostatic measurements. Urine output and signs of acute kidney injury. Electrolytes comprehensively.

Use one RAAS inhibitor (either ACE inhibitor or ARB) at the maximum tolerated dose rather than dual blockade. Spironolactone, eplerenone, or SGLT-2 inhibitors may provide additional renoprotective benefits in appropriate patients as add-on therapy to a single RAAS inhibitor.